|
SCIENTIFIC AGENDA
Friday, December 1, 2006
7:00 am
Breakfast
8:00 am
Welcome and introduction
Stephen B. Hanauer, MD and Richard
P. MacDermott, MD
Session I: Advances in the
therapy of IBD
Co-moderators: Edward V. Loftus, Jr,
MD and David T. Rubin, MD
8:10 am
What is new and clinically relevant
regarding 5-ASA products and steroids
in IBD?
Gary R. Lichtenstein, MD
8:30 am
Optimizing the use of immunomodulators
in IBD: 6-Mercaptopurine, azathioprine
and methotrexate
Bruce E. Sands, MD
8:50 am
Positioning currently available biological
therapies
William J. Sandborn, MD
9:10 am
Future therapies in IBD
Stephen B. Hanauer, MD
9:30 am
Panel discussion
10:00 am
Coffee break and poster viewing
Session IIA: Selected topics
in IBD
Co-moderators: Maria T. Abreu, MD
and Russell D. Cohen, MD
10:30 am
What does the changing epidemiology
of IBD tell us and have our medications
changed the natural history of IBD?
Edward V. Loftus, Jr, MD
10:50 am
The role of endoscopy in IBD
William J. Tremaine, MD
11:10 am
The dysfunctional pouch
Bo Shen, MD
11:30 am
Perianal disease and fistulae in Crohn’s
disease
David A. Schwartz, MD
11:50 am
Panel discussion
Session IIB: Nurses symposium
Moderator: Susan Peck, MSN, CRNP
10:30 am
Introduction
Susan Peck, MSN, CRNP
10:40 am
Laproscopic surgery in IBD: What nurses
need to know
Michele Rubin, RN, MS, APN-CNS, CGRN
11:05 am
Ostomy care: Approach to the patient
expecting a stoma and common stoma
problems
Janice C. Colwell, RN, MS, CWOCN
11:30 am
Pediatric IBD: The issues that make
kids different
Susan Peck, MSN, CRNP
11:55 am
Panel discussion
12:15 pm
Lunch break
12:30 pm
Luncheon satellite symposium supported
by Procter & Gamble Pharmaceuticals,
Inc.
The IBD Challenge: UC Case Management
Strategies
Session III: Case-based breakout
sessions
2:00 pm – 2:30 pm
All talks are 30 minutes, begin
at 2:00 pm and repeat at 2:45 pm
Cancer surveillance and chemoprevention
in Crohn’s disease and ulcerative
colitis: What should we do about
low-grade dysplasia, polyps and
therapy to prevent cancer development?
Case studies
David T. Rubin, MD and Thomas A.
Ullman, MD
Advances in radiological imaging
and interpretation of capsule endoscopy
findings in IBD: Case studies
Asher Kornbluth, MD and Edward V.
Loftus, Jr, MD
Immunomodulators and biologics
in pediatric IBD: When and how long
to use: Case studies
Subra Kugathasan, MD and Joel R.
Rosh, MD
Use of TPMT and 6-MP metabolites
to optimize 6-MP and AZA use in
IBD: Case studies
Maria T. Abreu, MD and Marla C.
Dubinsky, MD
Medical-surgical management challenges
in IBD: Case studies
Bo Shen, MD and William J. Tremaine,
MD
3:40 pm
Afternoon satellite symposium supported
by UCB, Inc.
Strategies for Using Anti-TNF Agents:
A Multi-National Case-Based Discussion
5:00 pm
Reception supported by UCB, Inc.
Saturday, December 2, 2006
6:50 am
Breakfast satellite symposium supported
by Abbott Laboratories
Crohn's Disease: Interventions and
Strategies – 2006 “Challenging Cases”
IBD
Clinical track A (parallel with Research
Track B)
8:00 am
Welcome and introduction
Stephen B. Hanauer, MD and Richard
P. MacDermott, MD
Session
IV A: Advances in the management of
IBD
Co-moderators: Gary R. Lichtenstein,
MD and Bruce E. Sands, MD
8:10 am
Side effects of IBD medications: How
and what do we tell our patients?
Corey A. Siegel, MD
8:30 am
Compliance with medications in IBD
Sunandra V. Kane, MD, MSPH
8:50 am
Fertility and pregnancy in IBD
Uma Mahadevan, MD
9:10 am
Treatment guidelines and how to interpret
them
Russell D. Cohen, MD
9:30 am
Panel discussion
10:00 am
Coffee break and poster viewing
Session
V A: Debates: Current controversies
in IBD
Co-moderators: Marla C. Dubinsky,
MD and William J. Tremaine, MD
10:30 am
Pro: Cyclosporine is the treatment
of choice for acute severe refractory
ulcerative colitis in the hospitalized
patient
Daniel H. Present, MD
10:50 am
Con: Biologics are the treatment of
choice for acute severe refractory
ulcerative colitis in the hospitalized
patient
Stephen B. Hanauer, MD
11:10 am
Panel discussion
11:30 am
Pro: There is good evidence that biologics
are appropriate as first-line therapy
for Crohn’s disease
Gary R. Lichtenstein, MD
11:50 am
Con: There is no good evidence that
biologics are appropriate as first-line
therapy for Crohn’s disease
Asher A. Kornbluth, MD
12:10 pm
Panel discussion
12:20 pm
Lunch break
12:30 pm
L uncheon satellite symposium supported
by Centocor, Inc.
Emerging Treatment Issues with Biologics
in Inflammatory Bowel Diseases
Session
VI A: Case-based breakout sessions
2:00 pm – 2:30
pm
All talks are 30 minutes, begin
at 2:00 pm and repeat at 2:45 pm
Biomarkers
in IBD: When and how to use them:
Case studies
Maria T. Abreu, MD and Marla C.
Dubinsky, MD
Challenges
in the care of the very young and
the adolescent patients with IBD:
Case studies
Subra Kugathasan, MD and Joel R.
Rosh, MD
Extraintestinal
manifestations of IBD: Evidence
vs. experience in management: Case
studies
Robert Burakoff, MD and Bret A.
Lashner, MD
What should
be the end-point for treatment of
ulcerative colitis and/or Crohn’s
disease? Case studies
Edward V. Loftus, Jr, MD and Bruce
E. Sands, MD
3:40 pm
Afternoon satellite symposium supported
by Shire Pharmaceuticals
Optimization of 5-ASA Therapies in
IBD
5:00 pm
Reception supported by Shire Pharmaceuticals
IBD
research track B (parallel with Clinical
Track A)
8:00 am
Welcome and introduction
Jonathan Braun, MD, PhD and Lloyd
F. Mayer, MD
Session
IV B: State-of-the-art lectures: Advances
in IBD basic research
Co-moderators: Jonathan Braun, MD,
PhD and Lloyd F. Mayer, MD
8:10 am
Genetics in IBD
Judy H. Cho, MD
8:30 am
Bacteria in IBD
R. Balfour Sartor, MD
8:50 am
Effector mechanisms in IBD
Charles O. Elson, III, MD
9:10 am
Regulatory T cells in IBD
Casey T. Weaver, MD
9:30 am
Panel discussion
10:00 am
Coffee break and poster viewing
Session
V B: State-of-the-art lectures: Advances
in IBD basic research II
Co-moderators: Charles O. Elson, III,
MD and Ivan J. Fuss, MD
10:30 am
Innate immunity in IBD
Jonathan Braun, MD, PhD
10:50 am
Epithelial cells in IBD
Lloyd F. Mayer, MD
11:10 am
Mechanisms of inflammation in IBD
Sean P. Colgan, PhD
11:30 am
Healing the intestinal epithelial
barrier: Potential new therapies
Jerrold R. Turner, MD, PhD
11:50 am
There is no good evidence that biologics
are appropriate as first-line therapy
for Crohn’s disease
Asher Kornbluth, MD
12:10 pm
Panel discussion
12:20 pm
Lunch break
12:30 pm
Research lunch in poster viewing area
Session
VI B: Original basic research abstract
presentations
Co-moderators: Sean P. Colgan, PhD
and Casey T. Weaver, MD
2:00 pm
Keynote lecturer
Mucus barrier function, intestinal
flora and IBD
Alexander Swidsinski, MD
2:20 pm
Oral treatment of mice with adenosine
A2A receptor agonist inhibits T cell
mediated colitis
Peter Ernst, DVM, PhD
2:30 pm
Novel methods to treat inflammation
by disrupting hepoxilin A3 synthesis
or secretion
Beth McCormick, PhD
2:40 pm
PAMPs and DAMPs in IBD
Katsuyos Matsuoka, MD, PhD
2:50 pm
Regulatory B cells modulate IL-17
producing CD4 T cells and CD8 T cells
in an animal model of Galpha i2 KO
T cells induced mucosal and systemic
inflammation
Bo Wei, MD, PhD
3:00 pm
STAT5B maintains gut mucosal tolerance
in Crohn's disease and murine colitis
Xiaonan Han, PhD
3:10 pm
Alternatively activated macrophages
in intestinal helminth infection:
Effects on concurrent bacterial enteritis
Bobby Cherayil
3:20 pm
Coffee break
3:40 pm
Pharmacological inhibition of gut
homing CCR9 T-cells alters disease
severity in murine models of inflammatory
bowel disease
Thomas J. Schall
3:50 pm
Metalloproteinase-9 (MMP-9) regulates
intestinal goblet cell specific gene
expression: Implications for the role
of MMP-9 in the pathogenesis of colitis
Pallavi Garg, PhD
4:00 pm
Non-receptor tyrosine kinase jak3
regulates mucosal restitution
Narendra Kumar, PhD
4:10 pm
A novel, hydrogen sulfide-releasing
mesalamine derivative (ATB-429) exhibits
enhanced anti-inflammatory and analgesic
activity in experimental colitis
John Wallace, PhD
4:20 pm
Eosinophils and eosinophil chemokines,
CCL11, CCL24 and CCL26, in refractory
pediatric Crohn’s disease
Simon Hogan, PhD
4:30 pm
Glutathione peroxidase prevents inflammation-associated
gene mutations in mouse ileum and
colon
Fong-Fong Chu, PhD
4:40 pm
Novel targets identified in gene expression
profiles from patients with inflammatory
bowel disease
Philip Alex, MD
4:50 pm
Adjourn
Sunday, December 3, 2006
7:00 am
Breakfast
8:00 am
Welcome and introduction
Stephen B. Hanauer, MD and Richard
P. MacDermott, MD
Session VII: State-of-the-art
lectures: Advances in translational
research in IBD
Co-Moderators: Lloyd F. Mayer, MD
and R. Balfour Sartor, MD
8:10 am
Future strategies against adaptive
immunity for IBD treatment
Scott Plevy, MD
8:30 am
Strategies against innate immunity
for IBD treatment
Maria T. Abreu, MD
8:50 am
Tolerance immunotherapy strategies
for IBD treatment
Lloyd F. Mayer, MD
9:10 am
Strategies to induce apoptosis for
IBD treatment
Ivan J. Fuss, MD
9:30 am
Panel discussion
10:00 am
Coffee break and poster viewing
Session VIII: Original clinical
research abstract presentations
Co-Moderators: Stephen B. Hanauer,
MD and Richard P. MacDermott, MD
10:30 am
Keynote lecturer
IL-23 receptor polymorphism
Richard H. Duerr, MD
10:50 am
Intestinal transplantation for end
stage Crohn’s disease: Therapeutic
efficacy and risk of recurrence
Kareem Abu-Elmagd, MD, PhD
11:00 am
Linear growth during infliximab therapy:
Results of the REACH multicenter study
T. Walters
11:10 am
Traficet-EN (CCX282-B), an orally
active inhibitor of chemokine receptor
CCR9, for treatment of Crohn's disease
Pirow Bekker, MD
11:20 am
Efficacy and safety of certolizumab
pegol in patients with prior influximab
use
Stephen B. Hanauer, MD
11:30 am
Patients’ perceptions and experiences
of ulcerative colitis: An internet-based
survey of the Crohn’s and Colitis
Foundation of America (CCFA)
Edward V. Loftus, Jr, MD
11:40 am
Improvement in health related quality
of life in infliximab-treated moderate-to-severe
active ulcerative colitis patients:
Improvement overall and baseline disease
activity
Bruce E. Sands, MD
11:50 am
Endoscopically measured mucosal healing
correlated with response to therapy
in moderately active UC
David T. Rubin, MD
12:00 pm
Magnetization transfer MRI for quantitative
assessment of intestinal fibrosis
in Crohn's disease
Jeremy Adler, MD
12:10 pm
Summary and adjourn
Stephen B. Hanauer, MD and Richard
P. MacDermott, MD
|
